{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:28Z","timestamp":1792783288057,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"INSPIRE Fellowship, Department of Science and Technology, Ministry of Science and Technology, Government of India","award":["IF180660"],"award-info":[{"award-number":["IF180660"]}],"id":[{"id":"https:\/\/ror.org\/03emtbt60","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03404-5","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:07:30Z","timestamp":1790309250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TGF-\u03b22 promotes autophagy-mediated resistance to doxorubicin in metastatic colon cancer cells via HMGB1"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8676-6531","authenticated-orcid":false,"given":"Sruthi","family":"Sritharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7143-352X","authenticated-orcid":false,"given":"Tamilselvan","family":"Jayavelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-8622","authenticated-orcid":false,"given":"Nageswaran","family":"Sivalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"3404_CR1","doi-asserted-by":"publisher","unstructured":"Saoudi Gonzalez N, et al. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications. Cancers (Basel). 2023;15(16). https:\/\/doi.org\/10.3390\/cancers15164020.","DOI":"10.3390\/cancers15164020"},{"issue":"1","key":"3404_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40880-017-0206-7","volume":"36","author":"CN Qian","year":"2017","unstructured":"Qian CN, Mei Y, Zhang J. Cancer metastasis: issues and challenges. Chin J Cancer. 2017;36(1):38. https:\/\/doi.org\/10.1186\/s40880-017-0206-7.","journal-title":"Chin J Cancer"},{"issue":"5\u20136","key":"3404_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1615\/CritRevOncog.v20.i5-6.150","volume":"20","author":"Y Fontebasso","year":"2015","unstructured":"Fontebasso Y, Dubinett SM. Drug Development for Metastasis Prevention. Crit Rev Oncog. 2015;20(5\u20136):449\u201373. https:\/\/doi.org\/10.1615\/CritRevOncog.v20.i5-6.150.","journal-title":"Crit Rev Oncog"},{"key":"3404_CR4","doi-asserted-by":"publisher","first-page":"119527","DOI":"10.1016\/j.lfs.2021.119527","volume":"278","author":"S Sritharan","year":"2021","unstructured":"Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021;278:119527. https:\/\/doi.org\/10.1016\/j.lfs.2021.119527.","journal-title":"Life Sci"},{"key":"3404_CR5","doi-asserted-by":"publisher","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci. 2020;21(9). https:\/\/doi.org\/10.3390\/ijms21093233.","DOI":"10.3390\/ijms21093233"},{"issue":"5","key":"3404_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/bjc.1996.432","volume":"74","author":"H Robson","year":"1996","unstructured":"Robson H, et al. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer. 1996;74(5):753\u20138. https:\/\/doi.org\/10.1038\/bjc.1996.432.","journal-title":"Br J Cancer"},{"issue":"5","key":"3404_CR7","first-page":"549","volume":"4","author":"E Friedman","year":"1995","unstructured":"Friedman E, et al. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev. 1995;4(5):549\u201354.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"41","key":"3404_CR8","doi-asserted-by":"publisher","first-page":"16618","DOI":"10.1073\/pnas.1117610109","volume":"109","author":"J Liu","year":"2012","unstructured":"Liu J, et al. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A. 2012;109(41):16618\u201323. https:\/\/doi.org\/10.1073\/pnas.1117610109.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"46","key":"3404_CR9","doi-asserted-by":"publisher","first-page":"e23024","DOI":"10.1097\/MD.0000000000023024","volume":"99","author":"Y Tu","year":"2020","unstructured":"Tu Y, et al. TGF-beta2 is a Prognostic Biomarker Correlated with Immune Cell Infiltration in Colorectal Cancer: A STROBE-compliant article. Med (Baltim). 2020;99(46):e23024. https:\/\/doi.org\/10.1097\/MD.0000000000023024.","journal-title":"Med (Baltim)"},{"issue":"20","key":"3404_CR10","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1038\/sj.onc.1202642","volume":"18","author":"M Miyaki","year":"1999","unstructured":"Miyaki M, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 1999;18(20):3098\u2013103. https:\/\/doi.org\/10.1038\/sj.onc.1202642.","journal-title":"Oncogene"},{"key":"3404_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03380-6","author":"S Sritharan","year":"2024","unstructured":"Sritharan S, Sivalingam N. Doxorubicin-induced chemoresistance in Duke\u2019s type B colon adenocarcinoma cell line is aggravated in the presence of TGF-beta2 through non-apoptotic cell death. Clin Transl Oncol. 2024. https:\/\/doi.org\/10.1007\/s12094-023-03380-6.","journal-title":"Clin Transl Oncol"},{"key":"3404_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12291-024-01247-3","author":"S Sritharan","year":"2024","unstructured":"Sritharan S, Sivalingam N. Secretion of IL-6 and TGF-\u03b22 by Colon Cancer Cells May Promote Resistance to Chemotherapy. Ind J Clin Biochem. 2024. https:\/\/doi.org\/10.1007\/s12291-024-01247-3.","journal-title":"Ind J Clin Biochem"},{"issue":"5","key":"3404_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ccr.2012.08.013","volume":"22","author":"A Calon","year":"2012","unstructured":"Calon A, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571\u201384. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.013.","journal-title":"Cancer Cell"},{"issue":"10","key":"3404_CR14","doi-asserted-by":"publisher","first-page":"7883","DOI":"10.1007\/s11033-020-05866-w","volume":"47","author":"J Jayarajan","year":"2020","unstructured":"Jayarajan J, et al. Curcumin induces chemosensitization to doxorubicin in Duke\u2019s type B coloadenocarcinoma cell line. Mol Biol Rep. 2020;47(10):7883\u201392. https:\/\/doi.org\/10.1007\/s11033-020-05866-w.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"3404_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1593\/neo.04640","volume":"7","author":"SK Halder","year":"2005","unstructured":"Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005;7(5):509\u201321. https:\/\/doi.org\/10.1593\/neo.04640.","journal-title":"Neoplasia"},{"issue":"1\u20132","key":"3404_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1\u20132):55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4.","journal-title":"J Immunol Methods"},{"issue":"4","key":"3404_CR17","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/molecules16042944","volume":"16","author":"M Al-Qubaisi","year":"2011","unstructured":"Al-Qubaisi M, et al. Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells. Molecules. 2011;16(4):2944\u201359. https:\/\/doi.org\/10.3390\/molecules16042944.","journal-title":"Molecules"},{"issue":"1","key":"3404_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12935-014-0142-4","volume":"14","author":"F Xu","year":"2014","unstructured":"Xu F, et al. Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell Int. 2014;14(1):142. https:\/\/doi.org\/10.1186\/s12935-014-0142-4.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"3404_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/toxsci\/kfp101","volume":"110","author":"H Zhang","year":"2009","unstructured":"Zhang H, et al. Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009;110(2):376\u201388. https:\/\/doi.org\/10.1093\/toxsci\/kfp101.","journal-title":"Toxicol Sci"},{"key":"3404_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jcb.240630705","volume":"26","author":"GJ Kelloff","year":"1996","unstructured":"Kelloff GJ, et al. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl. 1996;26:54\u201371. https:\/\/doi.org\/10.1002\/jcb.240630705.","journal-title":"J Cell Biochem Suppl"},{"issue":"24","key":"3404_CR21","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1242\/jcs.195057","volume":"129","author":"MP Thome","year":"2016","unstructured":"Thome MP, et al. Ratiometric analysis of Acridine Orange staining in the study of acidic organelles and autophagy. J Cell Sci. 2016;129(24):4622\u201332. https:\/\/doi.org\/10.1242\/jcs.195057.","journal-title":"J Cell Sci"},{"key":"3404_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0076-6879(08)03606-9","volume":"452","author":"CL Vazquez","year":"2009","unstructured":"Vazquez CL, Colombo MI. Assays to assess autophagy induction and fusion of autophagic vacuoles with a degradative compartment, using monodansylcadaverine (MDC) and DQ-BSA. Methods Enzymol. 2009;452:85\u201395. https:\/\/doi.org\/10.1016\/S0076-6879(08)03606-9.","journal-title":"Methods Enzymol"},{"issue":"6","key":"3404_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41388-021-02128-2","volume":"41","author":"P Frey","year":"2022","unstructured":"Frey P, et al. SMAD4 mutations do not preclude epithelial-mesenchymal transition in colorectal cancer. Oncogene. 2022;41(6):824\u201337. https:\/\/doi.org\/10.1038\/s41388-021-02128-2.","journal-title":"Oncogene"},{"issue":"8","key":"3404_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/sj.bjc.6605610","volume":"102","author":"DD Fang","year":"2010","unstructured":"Fang DD, et al. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer. 2010;102(8):1265\u201375. https:\/\/doi.org\/10.1038\/sj.bjc.6605610.","journal-title":"Br J Cancer"},{"issue":"1","key":"3404_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"10207","key":"3404_CR26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, et al. Colorectal cancer. Lancet. 2019;394(10207):1467\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(19)32319-0.","journal-title":"Lancet"},{"issue":"1","key":"3404_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1399-0004.2008.01091.x","volume":"75","author":"D Calva-Cerqueira","year":"2009","unstructured":"Calva-Cerqueira D, et al. The rate of germline mutations and large deletions of SMAD4 and BMPR1A in juvenile polyposis. Clin Genet. 2009;75(1):79\u201385. https:\/\/doi.org\/10.1111\/j.1399-0004.2008.01091.x.","journal-title":"Clin Genet"},{"issue":"5C","key":"3404_CR28","first-page":"3907","volume":"20","author":"M Diez","year":"2000","unstructured":"Diez M, et al. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas. Anticancer Res. 2000;20(5\u00a0C):3907\u201312.","journal-title":"Anticancer Res"},{"issue":"3","key":"3404_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/(sici)1097-0142(19990201)85:3<554::aid-cncr6>3.0.co;2-x","volume":"85","author":"KS Shim","year":"1999","unstructured":"Shim KS, et al. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer. 1999;85(3):554\u201361. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19990201)85:3%3C554::aid-cncr6%3E3.0.co;2-x.","journal-title":"Cancer"},{"issue":"3","key":"3404_CR30","doi-asserted-by":"publisher","first-page":"e90353","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris JC, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE. 2014;9(3):e90353. https:\/\/doi.org\/10.1371\/journal.pone.0090353.","journal-title":"PLoS ONE"},{"key":"3404_CR31","doi-asserted-by":"publisher","unstructured":"Eslami M, et al. Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review. Biomedicines. 2024;12(1). https:\/\/doi.org\/10.3390\/biomedicines12010183.","DOI":"10.3390\/biomedicines12010183"},{"issue":"1","key":"3404_CR32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1186\/s12885-016-2790-3","volume":"16","author":"B Guo","year":"2016","unstructured":"Guo B, et al. Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells. BMC Cancer. 2016;16(1):762. https:\/\/doi.org\/10.1186\/s12885-016-2790-3.","journal-title":"BMC Cancer"},{"issue":"11","key":"3404_CR33","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.4161\/auto.21654","volume":"8","author":"T Saha","year":"2012","unstructured":"Saha T. LAMP2A overexpression in breast tumors promotes cancer cell survival via chaperone-mediated autophagy. Autophagy. 2012;8(11):1643\u201356. https:\/\/doi.org\/10.4161\/auto.21654.","journal-title":"Autophagy"},{"issue":"2","key":"3404_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bbrc.2016.06.057","volume":"477","author":"JH Park","year":"2016","unstructured":"Park JH, et al. PI3K\/Akt\/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy. Biochem Biophys Res Commun. 2016;477(2):277\u201382. https:\/\/doi.org\/10.1016\/j.bbrc.2016.06.057.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"3404_CR35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3892\/mmr.2015.3356","volume":"12","author":"J Li","year":"2015","unstructured":"Li J, et al. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor beta signaling in HCT116 colon cancer cells. Mol Med Rep. 2015;12(1):192\u20138. https:\/\/doi.org\/10.3892\/mmr.2015.3356.","journal-title":"Mol Med Rep"},{"issue":"9","key":"3404_CR36","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41416-020-0783-0","volume":"122","author":"Z Yuan","year":"2020","unstructured":"Yuan Z, et al. Targeting CD133 reverses drug-resistance via the AKT\/NF-kappaB\/MDR1 pathway in colorectal cancer. Br J Cancer. 2020;122(9):1342\u201353. https:\/\/doi.org\/10.1038\/s41416-020-0783-0.","journal-title":"Br J Cancer"},{"key":"3404_CR37","doi-asserted-by":"publisher","unstructured":"Wu Z, et al. Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies. Int J Mol Sci. 2024;25(6). https:\/\/doi.org\/10.3390\/ijms25063141.","DOI":"10.3390\/ijms25063141"},{"issue":"15","key":"3404_CR38","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1093\/emboj\/cdf411","volume":"21","author":"H Mori","year":"2002","unstructured":"Mori H, et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J. 2002;21(15):3949\u201359. https:\/\/doi.org\/10.1093\/emboj\/cdf411.","journal-title":"EMBO J"},{"issue":"6","key":"3404_CR39","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/jid.2008.323","volume":"129","author":"U Anderegg","year":"2009","unstructured":"Anderegg U, et al. ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol. 2009;129(6):1471\u201382. https:\/\/doi.org\/10.1038\/jid.2008.323.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3404_CR40","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/art.27410","volume":"62","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, et al. Induction of CD44 cleavage in articular chondrocytes. Arthritis Rheum. 2010;62(5):1338\u201348. https:\/\/doi.org\/10.1002\/art.27410.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3404_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbamcr.2005.02.006","volume":"1745","author":"J Cichy","year":"2005","unstructured":"Cichy J, Kulig P, Pure E. Regulation of the release and function of tumor cell-derived soluble CD44. Biochim Biophys Acta. 2005;1745(1):59\u201364. https:\/\/doi.org\/10.1016\/j.bbamcr.2005.02.006.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"3404_CR42","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/sj.onc.1206298","volume":"22","author":"D Murakami","year":"2003","unstructured":"Murakami D, et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene. 2003;22(10):1511\u20136. https:\/\/doi.org\/10.1038\/sj.onc.1206298.","journal-title":"Oncogene"},{"issue":"23","key":"3404_CR43","doi-asserted-by":"publisher","first-page":"18995","DOI":"10.1074\/jbc.M111.318774","volume":"287","author":"KE Miletti-Gonzalez","year":"2012","unstructured":"Miletti-Gonzalez KE, et al. Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem. 2012;287(23):18995\u20139007. https:\/\/doi.org\/10.1074\/jbc.M111.318774.","journal-title":"J Biol Chem"},{"issue":"11","key":"3404_CR44","doi-asserted-by":"publisher","first-page":"8709","DOI":"10.18632\/oncotarget.3325","volume":"6","author":"Y Cho","year":"2015","unstructured":"Cho Y, et al. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget. 2015;6(11):8709\u201321. https:\/\/doi.org\/10.18632\/oncotarget.3325.","journal-title":"Oncotarget"},{"issue":"1","key":"3404_CR45","doi-asserted-by":"publisher","first-page":"7532","DOI":"10.1038\/s41598-019-43992-z","volume":"9","author":"BA Hocevar","year":"2019","unstructured":"Hocevar BA. Loss of Disabled-2 Expression in Pancreatic Cancer Progression. Sci Rep. 2019;9(1):7532. https:\/\/doi.org\/10.1038\/s41598-019-43992-z.","journal-title":"Sci Rep"},{"issue":"17","key":"3404_CR46","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-13-0954","volume":"19","author":"K Wu","year":"2013","unstructured":"Wu K, et al. The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res. 2013;19(17):4740\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0954.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3404_CR47","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/ncb3388","volume":"18","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, et al. Cathepsin-B-mediated cleavage of Disabled-2 regulates TGF-beta-induced autophagy. Nat Cell Biol. 2016;18(8):851\u201363. https:\/\/doi.org\/10.1038\/ncb3388.","journal-title":"Nat Cell Biol"},{"key":"3404_CR48","doi-asserted-by":"publisher","first-page":"530","DOI":"10.12659\/MSM.890531","volume":"20","author":"D Suren","year":"2014","unstructured":"Suren D, et al. The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit. 2014;20:530\u20137. https:\/\/doi.org\/10.12659\/MSM.890531.","journal-title":"Med Sci Monit"},{"issue":"8","key":"3404_CR49","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/labinvest.2009.47","volume":"89","author":"HJ Kang","year":"2009","unstructured":"Kang HJ, et al. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest. 2009;89(8):948\u201359. https:\/\/doi.org\/10.1038\/labinvest.2009.47.","journal-title":"Lab Invest"},{"key":"3404_CR50","doi-asserted-by":"publisher","first-page":"739145","DOI":"10.3389\/fonc.2021.739145","volume":"11","author":"J Li","year":"2021","unstructured":"Li J, et al. HMGB1 Promotes Resistance to Doxorubicin in Human Hepatocellular Carcinoma Cells by Inducing Autophagy via the AMPK\/mTOR Signaling Pathway. Front Oncol. 2021;11:739145. https:\/\/doi.org\/10.3389\/fonc.2021.739145.","journal-title":"Front Oncol"},{"key":"3404_CR51","doi-asserted-by":"publisher","first-page":"109450","DOI":"10.1016\/j.cbi.2021.109450","volume":"340","author":"SM Abdin","year":"2021","unstructured":"Abdin SM, et al. Nuclear factor-kappaB signaling inhibitors revert multidrug-resistance in breast cancer cells. Chem Biol Interact. 2021;340:109450. https:\/\/doi.org\/10.1016\/j.cbi.2021.109450.","journal-title":"Chem Biol Interact"},{"issue":"12","key":"3404_CR52","doi-asserted-by":"publisher","first-page":"9499","DOI":"10.1007\/s13277-015-3636-3","volume":"36","author":"Z Wang","year":"2015","unstructured":"Wang Z, et al. Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116\/L-OHP cells by preventing activation of NF-kappaB signaling and suppressing cAMP-responsive element transcriptional activity. Tumour Biol. 2015;36(12):9499\u2013510. https:\/\/doi.org\/10.1007\/s13277-015-3636-3.","journal-title":"Tumour Biol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03404-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:07:31Z","timestamp":1790309251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03404-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3404"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03404-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"298"}}